Melqart Asset Management UK Ltd Buys New Shares in Grifols, S.A. (NASDAQ:GRFS)

Melqart Asset Management UK Ltd purchased a new position in shares of Grifols, S.A. (NASDAQ:GRFS) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 183,351 shares of the biotechnology company’s stock, valued at approximately $1,628,000.

A number of other large investors also recently modified their holdings of GRFS. B. Riley Wealth Advisors Inc. bought a new stake in shares of Grifols in the 2nd quarter valued at about $359,000. Sei Investments Co. raised its stake in Grifols by 4.7% in the second quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock valued at $13,931,000 after buying an additional 100,131 shares during the period. Hantz Financial Services Inc. bought a new position in shares of Grifols during the 2nd quarter worth approximately $1,235,000. Natixis Advisors LLC lifted its holdings in Grifols by 116.0% during the 2nd quarter. Natixis Advisors LLC now owns 154,053 shares of the biotechnology company’s stock valued at $971,000 after purchasing an additional 82,723 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its holdings in shares of Grifols by 34.4% in the second quarter. Point72 Asset Management L.P. now owns 596,845 shares of the biotechnology company’s stock valued at $3,763,000 after purchasing an additional 152,700 shares during the last quarter.

Analyst Ratings Changes

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Price Performance

Shares of Grifols stock opened at $7.23 on Wednesday. The company has a quick ratio of 0.79, a current ratio of 2.26 and a debt-to-equity ratio of 1.11. Grifols, S.A. has a 1 year low of $5.30 and a 1 year high of $12.15. The firm’s 50 day moving average is $8.73 and its 200 day moving average is $8.10.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.